BioCentury
ARTICLE | Clinical News

Firdapse amifampridine: Phase III ongoing

October 21, 2013 7:00 AM UTC

Catalyst said an IDMC recommended continuation of a double-blind, placebo-controlled, international Phase III trial of Firdapse based on a review of safety and clinical data. The trial is evaluating Firdapse given 3-4 times daily in about 36 patients, who will receive a total daily dose of 30-80 mg, except in patients with moderate renal impairment, who will receive a starting dose of 10 mg. ...